I feel those that had the most influence in deciding what RAC's initial strategy was are no longer with the company (no prizes for guessing those).
I have more faith in those that have come back and recently joined the business will be able to navigate a much more positive and cunning plan.
And it will need to be a very cunning plan to turn the sentiment of investors around considering the work still to be done to attract a potential partnership and cash left.
I am looking forward to the release in the coming weeks.
Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-176
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
0.010(0.57%) |
Mkt cap ! $298.0M | |||
| Open | High | Low | Value | Volume |
| $1.73 | $1.83 | $1.73 | $272.0K | 152.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9998 | $1.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |